NEW YORK (Reuters Health) – The management of heart failure guided by an individualized target level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) doesn’t lead to clinically significant improvements…
NEW YORK (Reuters Health) – The IL-6 receptor-blocking monoclonal antibody tocilizumab inhibits joint damage in patients with rheumatoid arthritis that is not adequately controlled with methotrexate, according to…
NEW YORK (Reuters Health) – Results of a meta-analysis indicate that moderate doses of inhaled corticosteroids do not have any clinically relevant advantage over low doses in children…
NEW YORK (Reuters Health) – While elevated levels of anticardiolipin antibodies are associated with preeclampsia, measuring levels of anticardiolipin antibodies cannot be used to predict risk of preeclampsia…
NEW YORK (Reuters Health) – In the short term, cryoablation for atrioventricular nodal reentrant tachycardia (AVNRT) is as effective as radiofrequency catheter ablation, but 6-month recurrence rates are…
NEW YORK (Reuters Health) – Urologists from China report that the alpha-adrenergic receptor antagonist tamsulosin is a good first-line drug for outpatient medical expulsive therapy (MET) in patients…
NEW YORK (Reuters Health) – Over time, cervical intraepithelial neoplasia (CIN) grade 2 eventually resolves spontaneously in about two-thirds of adolescent and young adult women, according to findings…
NEW YORK (Reuters Health) – Ultrasound-guided high-intensity focused ultrasound (HIFU) ablation and the levonorgestrel intrauterine system (LNG-IUS) offer less invasive options for treating women with symptomatic adenomyosis, according…
NEW YORK (Reuters Health) – Conjugated bilirubin (CB) and direct bilirubin (DB) level measurements cannot be interpreted interchangeably, caution a group of pediatricians from San Francisco, California in…
NEW YORK (Reuters Health) – A molecular complex of aspirin and phosphatidylcholine called PL2200 seems to protect against acute gastroduodenal erosion and ulceration in older adults at risk…
